Champions Oncology, Inc 8-K, filed Oct 17, 2023
Champions Oncology, Inc. (CSBR)
8-K
2023-10-17
For: 2023-10-09
View Original
Added on
April 06, 2026
About this 8-K
Champions Oncology, Inc filed this 8-K on October 17, 2023, reporting on events of October 9, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 9, 2023
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||||||||||||
| of Incorporation) | Identification No.) | |||||||||||||
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201 ) 808-8400
N/A
(Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
INFORMATION TO BE INCLUDED IN THE REPORT
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | |||||||
On October 17, 2023, Champions Oncology, Inc. (the “Company”) announced the hiring and appointment of Brady Davis to serve as the Company’s President, effective as of October 9, 2023.
Mr. Davis brings more than 25 years of international experience leading medical instrument, software, data, and services companies in the healthcare space. As an executive leader, he has advanced commercial, product/market development, marketing, and bioinformatics teams in both established (Hewlett Packard, Oracle, Illumina) and developing (DNAnexus, Canexia Health) companies. Most recently, Mr. Davis served as Chief Business Officer at Imagia Canexia Health since March 2022, where he served prior as Senior Vice President - Business Development from November 2019 to March 2022. Prior to this, Mr. Davis served as Chief Strategy Officer and Vice President of Business and Market Development at DNANexus, Inc. from January 2017 to November 2019.
Mr. Davis will receive an annual base salary of $425,000 and will have the opportunity to earn a discretionary target incentive bonus of 50% of his base salary. He will also receive an equity award of 135,000 options to purchase the Company’s common stock, which will vest over a four-year period, and an equity award of 7,500 options to purchase the Company’s common stock which will vest over a one-year period.
There are no family relationships between Mr. Davis and any director or executive officer of the Company. There are no transactions between the Company and Mr. Davis that are subject to disclosure under Item 404(a) of Regulation S-K.
A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
| Item 9.01. | Financial Statements and Exhibits. | |||||||
(d)Exhibits
The following exhibit is filed herewith:
Exhibit No.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CHAMPIONS ONCOLOGY, INC. | |||||||||||
| (Registrant) | |||||||||||
| Date: October 17, 2023 | By: | /s/ Ronnie Morris | |||||||||
| Ronnie Morris | |||||||||||
| Chief Executive Officer | |||||||||||
Exhibit 99.1
NEWSOne University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104
Champions Oncology Announces the Addition of Brady Davis as President
HACKENSACK, NJ – OCTOBER 17th, 2023, 8:30AM - Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth.
"We are thrilled to have Brady join the already incredibly talented team here at Champions Oncology. Brady has deep healthcare, data, and oncology-specific experience and has a proven track record of building products and solutions that align with customer needs," stated Ronnie Morris, CEO of Champions Oncology.
Mr. Davis brings more than 25 years of international experience leading medical instrument, software, data, and services companies in the healthcare space. As an executive leader, he has advanced commercial, product/market development, marketing, and bioinformatics teams in both established (Hewlett Packard, Oracle, Illumina) and developing (DNAnexus, Canexia Health) companies. Mr. Davis will be collaborating with the executive team including the commercial and scientific teams to explore strategies to accelerate growth, both organically and in-organically.
“At a time of great advancements in cancer multi-omics research and bioinformatics, I am honored to join Champions Oncology at this juncture, in the efforts to help accelerate growth through our proprietary data and platforms,” said Mr. Davis. “I am confident that we will further solidify the company’s leadership position as the premier tech-enabled clinical and preclinical research partner, advancing precision oncology around the world."
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Contact:
Rachel Bunting, MS, MBA VP, Global Marketing Marketing@ChampionsOncology.com
Exhibit 99.1
Website: www.championsoncology.com Facebook: https://www.facebook.com/championsoncology/ LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: https://twitter.com/ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/